Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
10.13
-0.24 (-2.31%)
At close:
Mar 27, 2023, 4:00 PM
10.33
+0.20 (1.97%)
After-hours:
Mar 27, 2023, 6:51 PM EDT
Company Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.
Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs.
Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Immuneering Corporation
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. |
Contact Details
Address:
245 Main Street, Second Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617-500-8080 |
| Website | immuneering.com |
Stock Details
| Ticker Symbol | IMRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001790340 |
| CUSIP Number | 45254E107 |
| ISIN Number | US45254E1073 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Mallory Morales CPA | Vice President of Finance, Principal Financial and Accounting Officer and Treasurer |
| Paula George CPA | Senior Manager of Accounting and Operations |
| Michael D. Bookman J.D. | General Counsel and Secretary |
| Leah R. Neufeld | Chief People Officer |
| Dr. Scott Barrett M.D. | Chief Medical Officer |
| Dr. Mohamedi Kagalwala M.B.A., Ph.D. | Head of Neuroscience Development |
| Dr. Peter King Ph.D. | Head of Discovery and Vice President |
| Dr. Rajaraman Krishnan Ph.D. | Head of Neuroscience Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2023 | 10-K | Annual Report |
| Mar 6, 2023 | 8-K | Current Report |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 10, 2022 | 10-Q | Quarterly Report |
| Nov 10, 2022 | 8-K | Current Report |
| Sep 19, 2022 | 8-K/A | [Amend] Current report |